Clinical Trial: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Brief Summary: This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Detailed Summary:
Sponsor: Acerta Pharma BV

Current Primary Outcome: Determine the Maximum Tolerated Dose [ Time Frame: Cycle 1 (28 Days) ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Acerta Pharma BV

Dates:
Date Received: January 6, 2014
Date Started: January 2014
Date Completion:
Last Updated: December 14, 2016
Last Verified: December 2016